Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 183-191

  Erba, Harry P ^a  

^a Heerskink School of Medicine   (United States)

Author keywords

Acute myeloid leukemia (AML); Combination; Low intensity; Newly diagnosed; Novel agents; Older elderly

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BARASERTIB; BORTEZOMIB; CLOFARABINE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; GLASDEGIB; LENALIDOMIDE; PEVONEDISTAT; SAPACITABINE; TIPIFARNIB; TOSEDOSTAT; VALPROIC ACID; VOLASERTIB; VORINOSTAT; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY; ORGANOPHOSPHATE; QUINAZOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LEUKEMIA REMISSION; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; FEMALE; INTENSIVE CARE; LEUKEMIA, MYELOID, ACUTE; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYTARABINE; FEMALE; HUMANS; INTENSIVE CARE; LEUKEMIA, MYELOID, ACUTE; MALE; ORGANOPHOSPHATES; QUINAZOLINES; QUINOLONES;

EID: 84921433202     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.027     Document Type: Article

References (63)

1. National Cancer Institute. Cancer Statistics Review 1975-2003: Table I-11 median age of cancer patients at diagnosis, 2000-2003 by primary cancer site, race and sex. Available at: 〈http://seer.cancer.gov/archive/csr/1975_2003/results_single/sect_01_table.11_2pgs.pdf〉 (accessed: October 2013).
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Alibhai S.M., Leach M., Minden M.D., Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 2009, 115:2903-2911.
4. Menzin J., Lang K., Earle C.C., Kerney D., Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
5. Kantarjian H., O'Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer 2010, 116:4896-4901.
6. Appelbaum F.R., Rowe J.M., Radich J., Dick J.E. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2001, 6:62-86.
7. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology. Acute myeloid leukemia. Version 2. Available at: 〈http://www.nccn.org〉 (accessed: October 2013).
8. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
9. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
10. Kantarjian H.M., Thomas X.G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
11. Burnett A.K., Milligan D., Prentice A.G., Goldstone A.H., McMullin M.F., Hills R.K., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
12. Erba H.P. Has there been progress in the treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol 2010, 23:495-501.
13. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
14. Juliusson G., Antunovic P., Derolf A., Lehmann S., Möllgård L., Stockelberg D., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
15. Othus M., Kantarjian H., Petersdorf S., Ravandi F., Godwin J., Cortes J., et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia 2014, 28:289-292.
16. Klepin H.D., Geiger A.M., Tooze J.A., Kritchevsky S.B., Williamson J.D., Pardee T.S., et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013, 121:4287-4294.
17. Kantarjian H., O'Brien S., Cortes J., Giles F., Faderl S., Jabbour E., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
18. Rollig C., Thiede C., Gramatzki M., Aulitzky W., Bodenstein H., Bornhauser M., et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116:971-978.
19. Wheatley K., Brookes C.L., Howman A.J., Goldstone A.H., Milligan D.W., Prentice A.G., et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009, 145:598-605.
20. Pastore F., Dufour A., Benthaus T., Metzeler K.H., Maharry K.S., Schneider S., et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol 2014, 32:1586-1594.
21. Ferrara F., Schiffer C.A. Acute myeloid leukaemia in adults. Lancet 2013, 381:484-495.
22. Estey E. Therapeutic options for patients who are not eligible for intensive chemotherapy. Mediterr J Hematol Infect Dis 2013, 5:e2013050.
23. Dombret H., Seymour J.F., Butrym A., Wierzbowska A., Selleslag D., Jang J.H., et al. Results of a phase 3, multicenter, randomized, open-label study of azacitidine (AZA) vs conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (AML). Haematologica 2014, 99(suppl 1):788-789.
24. Astex Pharmaceuticals Inc. Press release: DACOGEN(R) approved in the European Union for the treatment of acute myeloid leukemia. Available at: 〈http://astx.com/content/resources/ASTX_News_2012_7_20_General_Releases.pdf〉 (accessed: August 2014).
25. Astex Pharmaceuticals Inc. Press release: FDA's Oncologic Drugs Advisory Committee (ODAC) votes to not support benefit/risk profile of Dacogen® (decitabine) in acute myeloid leukemia. Available at: 〈http://astx.com/content/resources/ASTX_News_2012_2_9_General_Releases.pdf〉 (accessed: October 2013).
26. Faderl S., Ravandi F., Huang X., Garcia-Manero G., Ferrajoli A., Estrov Z., et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008, 112:1638-1645.
27. Derissen E.J., Beijnen J.H., Schellens J.H. Concise drug review: azacitidine and decitabine. Oncologist 2013, 18:619-624.
28. Sekeres M.A., Steensma D.P. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol 2012, 30:4061-4063.
29. Tilly H., Castaigne S., Bordessoule D., Casassus P., Le Prise P.Y., Tertian G., et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990, 8:272-279.
30. Quintás-Cardama A., Ravandi F., Liu-Dumlao T., Brandt M., Faderl S., Pierce S., et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012, 120:4840-4845.
31. Yang J., Ikezoe T., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007, 110:2034-2040.
32. Giles F., Estey E., O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003, 98:2095-2104.
33. Liu X., Guo Y., Li Y., Jiang Y., Chubb S., Azuma A., et al. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-d-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 2005, 65:6874-6881.
34. Liu X., Kantarjian H., Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs 2012, 21:541-555.
35. Thomas X., Elhamri M. Tipifarnib in the treatment of acute myeloid leukemia. Biologics 2007, 1:415-424.
36. Rudolph D., Steegmaier M., Hoffmann M., Grauert M., Baum A., Quant J., et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009, 15:3094-3102.
37. Ling Y.H., Liebes L., Ng B., Buckley M., Elliott P.J., Adams J., et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002, 1:841-849.
38. Bonate P.L., Arthaud L., Cantrell W.R., Stephenson K., Secrist J.A., Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006, 5:855-863.
39. Kotla V., Goel S., Nischal S., Heuck C., Vivek K., Das B., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2:36.
40. Krige D., Needham L.A., Bawden L.J., Flores N., Farmer H., Miles L.E., et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 2008, 68:6669-6679.
41. Richon V.M. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006, 95:S2-S6.
42. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
43. Lin T.L., Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. Onco Targets Ther 2012, 5:47-58.
44. Fredly H., Gjertsen B.T., Bruserud O. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 2013, 5:12.
45. Burnett A.K., Hills R.K., Hunter A.E., Milligan D., Kell W.J., Wheatley K., et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013, 27:75-81.
46. Burnett A.K., Russell N.H., Culligan D., Cavanagh J., Kell J., Wheatley K., et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol 2012, 158:519-522.
47. Burnett A.K., Russell N.H., Hunter A.E., Milligan D., Knapper S., Wheatley K., et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013, 122:1384-1394.
48. Kantarjian H.M., Sekeres M.A., Ribrag V., Rousselot P., Garcia-Manero G., Jabbour E.J., et al. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk 2013, 13:559-567.
49. Kantarjian H.M., Martinelli G., Jabbour E.J., Quintas-Cardama A., Ando K., Bay J.O., et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 2013, 119:2611-2619.
50. Ravandi F., Faderl S., Cortes J.E., Garcia-Manero G., Jabbour E., Boone P.A., et al. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood 2011, 118. (Abstract 3630).
51. Ravandi F., Kadia T.M., Borthakur G., Wierda W.G., Goldberg S.L., Wetzler M., et al. Pooled analysis of elderly patients with newly diagnosed AML treated with sapacitabine and decitabine administered in alternating cycles. Blood 2012, 120. (Abstract 2630).
52. Döhner H., Lübbert M., Fiedler W., Fouillard L., Haaland A., Brandwein J.M., et al. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 2014, 124:1426-1433.
53. Nand S., Gundacker H., Godwin J.E., Willman C.L., Norwood T., Erba H.P., et al. A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol-report on the good-risk patients. J Clin Oncol 2012, 30. (Abstract 6502).
54. Nand S., Othus M., Godwin J.E., Willman C.L., Norwood T.H., Howard D.S., et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 2013, 122:3432-3439.
55. Pollyea D.A., Zehnder J., Coutre S., Gotlib J.R., Gallegos L., bdel-Wahab O., et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica 2013, 98:591-596.
56. Garcia-Manero G., Estey E.H., Jabbour E., Borthakur G., Kadia T., Naqvi K., et al. Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. Blood 2011, 118. (Abstract 608).
57. Cortes J., Feldman E., Yee K., Rizzieri D., Advani A., Charman A., et al. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol 2013, 14:354-362.
58. CTI issues statement regarding tosedostat clinical trial. Available at: 〈http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=1832542〉 (accessed: October 2013).
59. Blum W., Schwind S., Tarighat S.S., Geyer S., Eisfeld A.K., Whitman S., et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012, 119:6025-6031.
60. Fredly H., Ersvaer E., Kittang A.O., Tsykunova G., Gjertsen B.T., Bruserud O. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics 2013, 5:13.
61. Luger S.M. Treating the elderly patient with acute myelogenous leukemia. Hematol Am Soc Hematol Educ Program 2010, 2010:62-69.
62. Smith B.D., Karp J.E. What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma 2009, 9:S296-S301.
63. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.